Cingulate Stock Operating Margin
| CING Stock | USD 4.21 0.02 0.48% |
Fundamental analysis of Cingulate allows traders to better anticipate movements in Cingulate's stock price by examining its financial health and performance throughout various phases of its business cycle.
Cingulate | Build AI portfolio with Cingulate Stock |
Cingulate Company Operating Margin Analysis
Cingulate's Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
| Competition |
Based on the recorded statements, Cingulate has an Operating Margin of 0.0%. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The operating margin for all United States stocks is 100.0% lower than that of the firm.
Did you try this?
Run Portfolio Holdings Now
Portfolio HoldingsCheck your current holdings and cash postion to detemine if your portfolio needs rebalancing |
| All Next | Launch Module |
Cingulate Fundamentals
| Return On Equity | -4.18 | ||||
| Return On Asset | -1.2 | ||||
| Current Valuation | 19.74 M | ||||
| Shares Outstanding | 5.26 M | ||||
| Shares Owned By Insiders | 1.88 % | ||||
| Shares Owned By Institutions | 5.45 % | ||||
| Number Of Shares Shorted | 225.53 K | ||||
| Price To Book | 4.00 X | ||||
| Gross Profit | (10.68 M) | ||||
| EBITDA | (14.89 M) | ||||
| Net Income | (15.55 M) | ||||
| Cash And Equivalents | 8.2 M | ||||
| Cash Per Share | 0.73 X | ||||
| Total Debt | 5.1 M | ||||
| Debt To Equity | 0.08 % | ||||
| Current Ratio | 10.94 X | ||||
| Book Value Per Share | 1.13 X | ||||
| Cash Flow From Operations | (18.45 M) | ||||
| Short Ratio | 2.06 X | ||||
| Earnings Per Share | 135.02 X | ||||
| Target Price | 27.71 | ||||
| Number Of Employees | 13 | ||||
| Beta | -0.75 | ||||
| Market Capitalization | 22.06 M | ||||
| Total Asset | 14.86 M | ||||
| Retained Earnings | (108.49 M) | ||||
| Working Capital | 7.69 M | ||||
| Net Asset | 14.86 M |
About Cingulate Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cingulate's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cingulate using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cingulate based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Cingulate is a strong investment it is important to analyze Cingulate's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cingulate's future performance. For an informed investment choice regarding Cingulate Stock, refer to the following important reports:Check out Cingulate Piotroski F Score and Cingulate Altman Z Score analysis. For more detail on how to invest in Cingulate Stock please use our How to Invest in Cingulate guide.You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cingulate. If investors know Cingulate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cingulate listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Cingulate is measured differently than its book value, which is the value of Cingulate that is recorded on the company's balance sheet. Investors also form their own opinion of Cingulate's value that differs from its market value or its book value, called intrinsic value, which is Cingulate's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cingulate's market value can be influenced by many factors that don't directly affect Cingulate's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cingulate's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cingulate is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cingulate's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.